Exabis Library
Welcome to the e-CCO Library!
P614: The utility as a biomarker of faecal calprotectin for predicting the clinical outcome of granulocyte and monocyte adsorptive apheresis treatment in patients with ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P615 Safety of vedolizumab in the treatment of IBD in a single tertiary centre
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P615: Does smoking really influence the development and the outcomes of Inflammatory Bowel Disease in Asian population? Results from the Taiwanese patients
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P615: Efficacy of vedolizumab in patients with Crohn's disease may differ depending on the disease location: The UCLH experience
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P615: Improving IBD monitoring by understanding preanalytical faecal calprotectin variability
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P615: Rescue infliximab for acute severe colitis: a single-centre experience
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P615: The safety and efficacy of ustekinumab combined with sphincter-preserving surgery for perianal fistulizing Crohn's disease:a single-center retrospective study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P615: The unfinished symphony: golimumab is efficient in patients with refractory Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P616 IBD reference and biosimilar adalimumab CroSS over study (iBaSS): design considerations and methodology
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P616: Fatigue in pediatric inflammatory bowel diseases – systematic review and rates in a prospective cohort
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P616: Natural history and phenotype of inflammatory bowel disease with co-existent celiac disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P616: Safety of COVID-19 vaccines in patients with IBD
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P616: Sustainability of thiopurines monotherapy in ulcerative colitis: a nationwide analysis from the epi-IIRN cohort
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P616: Ustekinumab for refractory paediatric Crohn’s disease: experience from two UK tertiary referral centres
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P616: Utility of zinc protoporphyrin/haem ratio as a marker of iron deficiency with or without anaemia in patients with inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P617 Mesenchymal stromal cells of bone marrow reduce the risk of postoperative recurrence of Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P617: Dual biologic therapy in pediatric Inflammatory Bowel Disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P617: Evaluation of subclinical myocardial damage in patients with inflammatory bowel disease on treatment with biologics
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P617: Extraintestinal autoimmune phenomena during treatment with vedolizumab
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P617: Single-centre experience with biological treatment in budesonide-refractory microscopic colitis patients
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM